Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P050052/S174

RADIESSE Injectable Implant, RADIESSE Hands, RADIESSE (+) Lidocaine, Jawline indication

Merz North America, Inc. · Decision date Jan 13, 2026

FDA DECISIONP050052/S174

What did the FDA decide?

FDA records P050052/S174 as a supplement to PMA P050052, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Jan 13, 2026.

FDA approval order statement

adding a new surface area analyzer in quality control testing of calcium hydroxyapatite (CaHA) particles
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
General, Plastic Surgery
Decision date
Jan 13, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P050052/S174
Regulatory pathway
PMA supplement
Product code
LMH
Decision code
OK30
Decision date
Jan 13, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Implant, dermal, for aesthetic use.

Product code
LMH
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P050052/S173 · Related supplement

    RADIESSE INJECTABLE IMPLANT

  2. P050052/S174 received

    Application receipt date recorded by FDA.

  3. P050052/S174 · FDA decision

    30-Day Notice

  4. P050052/S175 · Related supplement

    RADIESSE Injectable Implant

  5. P050052/S176 · Related supplement

    RADIESSE Injectable Implant

  6. P050052/S177 · Related supplement

    P050052 RADIESSE Injectable Implant; RADIESSE Hands; RADIESSE (+) Lidocaine; Jawline indication

  7. P050052/S162 · Related supplement

    RADIESSE Injectable Implant

  8. P050052/S178 · Related supplement

    RADIESSE Injectable Implant, RADIESSE Hands

  9. P050052/S179 · Related supplement

    RADIESSE Injectable Implant

Timeline entries are records held by MedtechLedger for P050052. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P050052

Product / regulatory recordCompanyPathwayDecision dateSource
Merz North America, Inc.PMA supplementDec 12, 2025FDA
Merz North America, Inc.PMA supplementMar 18, 2026FDA
Merz North America, Inc.PMA supplementMar 24, 2026FDA
Merz North America, Inc.PMA supplementMar 24, 2026FDA
Merz North America, Inc.PMA supplementMar 31, 2026FDA
Merz North America, Inc.PMA supplementMay 14, 2026FDA
Merz North America, Inc.PMA supplementJun 26, 2026FDA

Explore the linked device profile

Other records with product code LMH

Product / regulatory recordCompanyPathwayDecision dateSource
AllerganPMA supplementNov 4, 2026FDA
Merz North America, Inc.PMA supplementNov 4, 2026FDA
Merz North America, Inc.PMA supplementOct 21, 2026FDA
Prollenium Medical Technologies, Inc.PMA supplementOct 14, 2026FDA
saypha ChiQP250021/S002
Croma-Pharma GmbHPMA supplementOct 8, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Merz North America, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
4133 Ct.ney Rd., Suite 10, Franksville, WI, 53126

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records